Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial

Obstetrics and Gynecology

Volumn 95, Issue 3, 2000, Pages 397-402

  Rein, David B ^a,b   Kassler, William J ^a,c   Irwin, Kathleen L ^a   Rabiee, Lara ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c New Hampshire Dept Hlth Hum Serv   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COST BENEFIT ANALYSIS; ECTOPIC PREGNANCY; FEMALE; FEMALE INFERTILITY; HOSPITAL COST; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; PELVIC INFLAMMATORY DISEASE; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROBABILITY;

COST OF ILLNESS; FEMALE; HEALTH EXPENDITURES; HUMANS; INFERTILITY, FEMALE; MODELS, STATISTICAL; PELVIC INFLAMMATORY DISEASE; PELVIC PAIN; PREGNANCY; PREGNANCY, ECTOPIC; UNITED STATES;

EID: 0033956290     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(99)00551-7     Document Type: Article

References (26)

1. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep. 47:(RR-1):1998;79-88.
2. Washington A.E., Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA. 266:1991;2565-2569.
3. Siegel J.E. Estimates of the economic burden of STDs Review of the literature with updates . Eng T.R., Butler W.T. Institute of Medicine. The hidden epidemic. 1997;330-356 National Academy Press, Washington DC.
4. American Social Health Association. STD counseling and treatment guide. Research Triangle Park, NC: 1995:209-19.
5. Haddix A.C., Hillis S.D., Kassler W.J. The cost effectiveness of azithromycin for chlamydia trachomatis infections in women. Sex Transm Dis. 22:1995;274-280.
6. Hillis S., Black C., Newhall J., Walsh C., Groseclose S.L. New opportunities for chlamydia prevention Applications of science to public health practice . Sex Transm Dis. 22:1995;197-202.
7. Prevention and managed care Opportunities for managed care organizations, purchasers of health care and public health agencies . MMWR Morb Mortal Wkly Rep. 44:(RR-14):1995;1-12.
8. National Center for Health Statistics. 1993, 1994, 1995 National hospital discharge survey: Public use data tape documentation. Hyattsville, MD: 1993-1995.
9. International classification of diseases, ninth revision, clinical modification (ICD-9-CM). 1996;Medicode Publications, Salt Lake City, UT.
10. Washington A.E., Arno P.S., Brooks M.A. The economic cost of pelvic inflammatory disease. JAMA. 255:1986;1735-1738.
11. Washington A.E., Cates W. Jr, Zaidi A.A. Hospitalizations for pelvic inflammatory disease Epidemiology and trends in the United States, 1975 to 1981 . JAMA. 251:1984;2529-2533.
12. Rolfs R.T., Galaid E.I., Zaidi A.A. Pelvic inflammatory disease Trends in hospitalizations and office visits, 1979 through 1988 . Am J Obstet Gynecol. 166:1992;983-990.
13. National Center for Health Statistics. 1994, 1995 National ambulatory medical care survey. Public-use data tape documentation. Hyattsville, MD: 1994-1995.
14. National Center for Health Statistics. 1994, 1995 National hospital ambulatory medical care survey - outpatient department file. Public-use data tape documentation. Hyattsville, MD: 1994-1995.
15. National Center for Health Statistics. 1994, 1995 National hospital ambulatory medical care survey - Emergency department file. Public-use tape documentation. Hyattsville, MD: 1994-1995.
16. National Center for Health Statistics. 1994, 1995 NAMCS and NHAMCS OD/ER Variance Files. Public-use tape. Hyattsville, MD: 1994-1995.
17. Software for Survey Data Analysis (SUDAAN), Version 7.50. 1997;Research Triangle Institute, Research Triangle Park, NC.
18. Shah B.V. SESUDAAN Standard errors program for computing standardized rates from sample survey data . 1981;Research Triangle Institute, Research Triangle Park, North Carolina.
19. Weström L., Mårdh P. Acute pelvic inflammatory disease (PID). Holmes K.K., Mårdh P., Sparling P.F., Wiesner P.J., Cates W. Jr, Lemon S.M., et al. Sexually transmitted diseases. 1990;593-613 McGraw-Hill Information Services Company, New York.
20. Landry D.J., Forrest J.D. Public health departments providing sexually transmitted disease services. Fam Plann Perspect. 28:1996;261-266.
21. ® database user's guide. 1997;The MEDSTAT Group Inc, Ann Arbor, MI.
22. Physicians' desk reference. 51st ed. 1997;Medical Economics Company, Montvale, NJ.
23. Haddix A.C., Teutsch S.M., Schaffer P.A., Duñet D.O. Prevention effectiveness A guide to decision analysis and economic evaluation . 1996;Oxford University Press, New York.
24. Curran J.W. Economic consequences of pelvic inflammatory disease in the United States. Am J Obstet Gynecol. 138:1980;848-851.
25. Van Voorhis BJ. Cost of therapy, infertility treatment: What is a cost-effective approach? Drug Benefit Trends July 1998:22-9.
26. Scholes D., Stergachis A., Heidrich F.E., Andrilla H., Holmes K.K., Stamm W.E. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 334:1996;1362-1366.